Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 134,015,088
  • Shares Outstanding, K 960,131
  • Annual Sales, $ 24,556 M
  • Annual Income, $ 3,232 M
  • 60-Month Beta 0.20
  • Price/Sales 5.39
  • Price/Cash Flow 20.38
  • Price/Book 39.22

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 1.49
  • Number of Estimates 4
  • High Estimate 1.53
  • Low Estimate 1.43
  • Prior Year 1.33
  • Growth Rate Est. (year over year) +12.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
127.69 +9.31%
on 12/18/19
141.97 -1.68%
on 01/16/20
+14.25 (+11.37%)
since 12/17/19
3-Month
101.36 +37.71%
on 10/23/19
141.97 -1.68%
on 01/16/20
+31.12 (+28.69%)
since 10/17/19
52-Week
101.36 +37.71%
on 10/23/19
141.97 -1.68%
on 01/16/20
+20.42 (+17.14%)
since 01/17/19

Most Recent Stories

More News
Pharma Stock Roundup: LLY Dermira Buyout Offer, Pipeline & Regulatory Updates

Lilly (LLY) offers to buy Dermira for $1.1 billion. AstraZeneca (AZN) and AbbVie (ABBV) provide pipeline updates.

MRK : 90.97 (-0.23%)
JNJ : 149.17 (+0.65%)
BMY : 66.72 (-0.09%)
ABBV : 88.00 (-1.41%)
AZN : 51.33 (+1.62%)
NVS : 95.93 (+0.87%)
LLY : 139.58 (-1.31%)
Novo Nordisk's Ozempic Gets FDA Nod for CV Risk Reduction

Novo Nordisk's (NVO) Ozempic gets FDA approval for reducing the risk of major adverse cardiovascular events in people with type II diabetes and established CVD.

PFE : 40.51 (-0.25%)
LLY : 139.58 (-1.31%)
NVO : 61.31 (unch)
GILD : 62.98 (-0.35%)
Emerging Markets Report: A Very Big Deal

It doesn't take an analyst to suggest that high value merger and acquisition activity in any industry is a bullish sign. And it assuredly doesn't take any research firm at all to suggest that an eczema...

LLY : 139.58 (-1.31%)
HOTH : 5.01 (-2.73%)
Eli Lilly (LLY) Gains But Lags Market: What You Should Know

Eli Lilly (LLY) closed the most recent trading day at $141.43, moving +0.23% from the previous trading session.

LLY : 139.58 (-1.31%)
NBCUniversal Unveils Peacock, A Free Premium Ad-Supported Streaming Service With Subscription Tiers

--Peacock Strikes Bundled Distribution Deals with Cox and Comcast, Bringing the Service to a Combined Total of More Than 24 Million Initial Subscribers

LLY : 139.58 (-1.31%)
CMCSA : 47.50 (+1.34%)
Lilly Confirms Date and Conference Call for Fourth-Quarter 2019 Financial Results Announcement

Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter and full-year 2019 financial results on Thursday, January 30, 2020. Lilly will also conduct a conference call on that day with the investment...

LLY : 139.58 (-1.31%)
J&J Seeks Label Expansion for Spravato Nasal Spray in EU

J&J (JNJ) seeks label expansion for its new nasal spray, Spravato (esketamine), for an expanded patient population in Europe.

BMY : 66.72 (-0.09%)
LLY : 139.58 (-1.31%)
AGN : 192.68 (-0.59%)
JNJ : 149.17 (+0.65%)
Bristol-Myers' Opdivo-Yervoy sBLA for NSCLC Accepted by FDA

The FDA accepts Bristol-Myers' (BMY) sBLA for the Opdivo-Yervoy combo for the first-line treatment of patients with metastatic or recurrent NSCLC with no EGFR or ALK genomic tumor aberrations.

MRK : 90.97 (-0.23%)
BMY : 66.72 (-0.09%)
LLY : 139.58 (-1.31%)
PFE : 40.51 (-0.25%)
Nektar's Pain Drug Gets Adverse Advisory Committee Decision

Nektar (NKTR) to stop development of chronic pain candidate, NKTR-181, following two FDA advisory committees' decision to not recommend its approval.

LLY : 139.58 (-1.31%)
BMY : 66.72 (-0.09%)
GILD : 62.98 (-0.35%)
NKTR : 22.48 (-5.94%)
Lilly to Launch Cheaper Versions of Humalog KwikPen Insulins

Eli Lilly (LLY) announced plans to launch cheaper version of its Humalog insulins, Mix75/25 KwikPen and Junior KwikPen.

SNY : 51.24 (+0.10%)
PFE : 40.51 (-0.25%)
NVO : 61.31 (unch)
LLY : 139.58 (-1.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade LLY with:

Business Summary

Eli Lilly and Company is a global healthcare leader that unites caring with discovery to make life better for people around the world. They were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and they remain true to that mission in all their...

See More

Key Turning Points

2nd Resistance Point 142.61
1st Resistance Point 141.09
Last Price 139.58
1st Support Level 138.71
2nd Support Level 137.85

See More

52-Week High 141.97
Last Price 139.58
Fibonacci 61.8% 126.46
Fibonacci 50% 121.67
Fibonacci 38.2% 116.87
52-Week Low 101.36

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar